Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

ID#: NCT03898479

Age: 18 - 65 years

Gender: All

Healthy Subjects: No

Study Phase: Phase 2/Phase 3

Recruitment Status: Enrolling by invitation

Start Date: April 04, 2019

End Date: May 01, 2023

Summary: The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
Eligibility:

Inclusion Criteria:

- Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial

Exclusion Criteria:

- Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis

- Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study medication

- Donation of blood at any point throughout the study and for 30 days after last dose of study medication
Find a Clinical Trial